Drs. Bresalier and Baron respond [3]

New England Journal of Medicine

Volumn 355, Issue 2, 2006, Pages 204-205

  Bresalier, Robert S ^a   Baron, John A ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ROFECOXIB;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLORECTAL ADENOMA; CORRELATION COEFFICIENT; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; PRIORITY JOURNAL; RISK FACTOR;

EID: 33745886257     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (3)

1. ICH-E1A. Guideline for industry. The extent of population exposure to assess clinical safety: for drugs intended for longterm treatment of non-life-threatening conditions. International Conference on Harmonization, March 1995:1-4. (Accessed June 22, 2006, at http://www.fda.gov/Cder/guidance/ iche1a.pdf.)
2. Council for International Organizations of Medical Sciences (CIOMS). Management of safety information from clinical trials: report of CIOMS Working Group VI. Geneva: World Health Organization, April 2005:189.
3. Correction to: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2006;355:221.